Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease by Sorrentino, Dario & Gray, James M
1Inflamm Bowel Dis • Volume XX, Number XX, XX 2021
Received for publications June 13, 2020; Editorial Decision September 24, 2020.
From the *IBD Center, Division of Gastroenterology, Virginia Tech Carilion 
School of Medicine, Roanoke, Virginia, USA; †Department of Clinical and 
Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy
Address correspondence to: Dario Sorrentino, MD, FRACP, Division 
of Gastroenterology, 3 Riverside Circle, Roanoke, VA 24016 (drsorrentino@
carilionclinic.org).
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press on 
behalf  of Crohn’s & Colitis Foundation.
Original research articles - clinical
Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly 
Predicts Therapeutic Response in Inflammatory Bowel Disease
Dario Sorrentino, MD, FRACP,*,† and James M. Gray*
Background: Fecal lactoferrin (FL) levels may mirror drug-induced changes in inflammation in ulcerative colitis and Crohn disease in a timely 
way and could be used to assess loss of response (LOR) to biologics.
Methods: This study is a retrospective outcome review in 61 patients on adalimumab, infliximab, or vedolizumab managed in our center and 
followed for 6 to 24 months. Patients were 1) in clinical remission or 2) were experiencing possible LOR.
Results: For group 1, in 71% of 31 patients, FL slowly increased during the therapeutic interval (R2 = 0.769; P < 0.001), thus reflecting increasing 
inflammation as drug concentrations decreased. In the remaining patients, FL was undetectable throughout the therapeutic interval because of a 
stronger suppression of inflammation. For group 2, in 30 patients negative for infections, FL levels measured 1 to 3 days after infusion/injection 
compared to preadministration values either increased (nonresponders)—in these patients the medication was switched to another class; partially 
decreased (partial responders)—the therapeutic interval was shortened; or were normal throughout (responders)—causes for symptoms unre-
lated to disease activity were found for all. After FL-based management, 3-month standardized clinical scores were normalized in both partial re-
sponders (0.58 ± 0.21 vs 0.13 ± 0.09; P < 0.001) and nonresponders (0.81 ± 0.17 vs 0.12 ± 0.08; P < 0.001), and FL levels dropped by up to 99%.
Conclusions: Levels of FL reflect drug-induced changes in mucosal inflammation in a timely way, thus enabling rapid assessment of therapeutic 
response in patients with ulcerative colitis and with Crohn disease. In patients with suspected LOR, FL levels before and after infusion/injection 
accurately separated responders, partial responders, and nonresponders. The strategy proposed here is simple, accurate, and easily applicable to 
clinical practice.
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INTRODUCTION
Response to therapy in inflammatory bowel disease 
(IBD)—both ulcerative colitis (UC) and Crohn’s disease 
(CD)—has classically been monitored by the severity of 
clinical symptoms1 and by endoscopy, a more objective 
but also more expensive and invasive tool. More recently, 
in patients on biologics, the measurement of  drug trough 
levels (TL) and of  antidrug antibodies—a strategy known 
as therapeutic drug monitoring (TDM)—has been widely 
used to assess/manage loss of  response (LOR) and pri-
mary nonresponse (PNR).2 Although TDM-based man-
agement may improve outcomes in IBD,2,3 this strategy is 
expensive and has practical shortcomings.4-9 Ideally, it is 
the individual patient disease burden that therapy should 
target.4, 10, 11 
Fecal markers of inflammation, specifically fecal lacto-
ferrin (FL) and fecal calprotectin (FC), seem to be accurate in-
dicators of intestinal mucosa inflammation,1 but their definitive 
role in IBD management still needs to be elucidated.12 In partic-
ular, it is unclear whether stool markers can accurately indicate 
immediate therapy-induced changes in IBD activity, a neces-
sary feature for the management of LOR. Previous studies have 
shown that FC levels in patients with IBD on biologics increase 
during the therapeutic interval—thus reflecting in a timely way 
the increasing inflammatory activity resulting from the progres-
sive neutralization of the medication.13 We have since confirmed 
such findings with FL and leveraged them to routinely evaluate 
patients’ immediate response to treatment when experiencing 
an apparent clinical flare. In this retrospective study we report 
the relevant data.
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METHODS
Study Design and Study Population
This retrospective study enrolled 61 patients with UC 
or CD diagnosed and staged according to established cri-
teria,14 treated with biologics (infliximab, adalimumab, and 
vedolizumab), and monitored as standard of care in our IBD 
center through the measurement of FL levels. Five of these pa-
tients were treated with infliximab-dyyb (Inflectra), but no dis-
tinction was made between Inflectra and infliximab-Remicade. 
The FL levels and clinical/laboratory data were collected from 
the patients’ electronic medical records. Data collected involved 
2 different groups of patients.
The first group (therapeutic interval group) consisted of 
patients on maintenance monotherapy in clinical remission; 
data included FL at baseline (measured within 1  month of 
initiating therapy) and FL measured at different times during 
the biologic therapeutic interval (8 weeks for vedolizumab/
infliximab, 2 weeks for adalimumab). The objective of this 
study was to confirm our original observation (obtained with 
FC) showing that in patients responding to biologics, fecal in-
flammatory markers mirror mucosal inflammation, which is 
inversely correlated to serum drug concentrations, in a timely 
way.13 It was anticipated that FL fluctuation during the thera-
peutic interval would not be detected in patients in profound/
biologic remission.
The second group (patients with suspected LOR) in-
cluded 30 patients on maintenance monotherapy with 
biologics apparently experiencing a disease flare as judged 
by pain and/or diarrhea and/or bleeding in whom stool 
studies (Clostridioides difficile, stool culture, ova and para-
sites) had excluded infection. No steroids or other medi-
cations were prescribed before the index FL tests. The FL 
levels were measured 1 to 3  days before and 2 to 3  days 
after infusion/injection (Fig.  1). Patients with elevated FL 
levels before infusion/injection were managed according to 
changes observed afterward. When FL returned to normal 
levels, patients were considered full responders and non-
IBD causes of  symptoms were sought. When FL decreased 
but did not return to normal, patients were considered par-
tial responders and the therapeutic interval was decreased 
(by 2-4 weeks for infliximab/vedolizumab and by 7 days for 
adalimumab). If  patients were already on the shortest in-
terval, then an immunomodulator was added. When FL 
levels increased after infusion/injection, patients were con-
sidered nonresponders and the medication was switched to a 
new one. We anticipated such increases in inflammation and 
FL levels in nonresponders because of  the progressive, time-
dependent nature of  uncontrolled disease activity. If  patients 
failed or had already failed the available biologic agents, 
then they underwent surgery. Patients in whom the FL levels 
were normal before infusion/injection (in all of  them levels 
remained normal afterward) were also considered full re-
sponders and no therapeutic changes were made. However, 
non-IBD causes for the symptoms were sought. 
Outcome data in this group included clinical assessment 
(see “Assessment of Clinical Disease Activity” below) and ad-
ditional predrug infusion/injection FL measurements and/or 
imaging/colonoscopy performed at 3  months after the index 
FL determination. Patients were also followed in the long term. 
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The goal of this study was to show that a stool marker–based 
approach can separate responders from partial responders and 
nonresponders based on symptom resolution and improvement 
of objective parameters of disease activity.
There was no direct patient involvement. The study con-
formed to the guidelines of the 1975 Declaration of Helsinki 
as reflected by Carilion Clinic Ethical Committee approval. No 
patient consent was deemed necessary.
Biomarker Testing
The FL was measured in samples collected during the 
first bowel movement of the day by the LACTOFERRIN 
SCAN (TECHLAB, Blacksburg, VA), an enzyme-linked immu-
nosorbent assay. Values ≤7.24 μg/mL are considered normal15. 
At the Carilion Clinic Laboratory, the lower limit to which the 
linearity of results has been validated is 6.25  μg/mL—which 
was the absolute value reported and analyzed for all results 
≤6.25  μg/mL. The FL values are presented by standard dec-
imal approximations of the real number by excess or defect. 
Routine blood and stool studies were performed using estab-
lished methods.
Assessment of Clinical Disease Activity
Clinical assessment was based on the Harvey-Bradshaw 
Index (HBI) for CD and the Partial Mayo Scoring Index (PMSI) 
for UC.16 For HBI, scores of <5, 5 to 7, 8 to 16, and >16 define 
remission, mild, moderate, and severe disease activity. The same 
activities are defined by the scores of 0 to 1, 2 to 4, 4 to 6, and 
7 to 9 for PMSI.
Statistical Analysis
Therapeutic interval group
This analysis focused on the relationship between FL 
values and the timing of test determination during the thera-
peutic interval for the 3 medications. Because the therapeutic 
intervals differed for the 3 medications (2 weeks for adalimumab 
and 8 weeks for infiximab/vedolizumab) and because the indi-
vidual absolute FL values also differed among patients, the data 
were normalized to percentage of baseline FL values (values 
before starting any therapy) and percentage of therapeutic in-
terval. All treatments were considered together because when 
treatment was considered as a second variable in the model and 
when interaction of treatment and timing was considered, nei-
ther one was found to be statistically significant. A repeated-
measures model using the percentage of FL as the outcome of 
the model was run initially, which showed the residuals to be 
right-skewed. Hence, FL values were log-transformed and per-
centages of baseline ln (FL) were calculated, with the resulting 
model residuals appearing much closer to being normally 
distributed. Data were then analyzed again with a repeated-
measures model using R version 3.6.1 and specific packages.17, 
18 The results of the analysis of variance F test for the effect of 
therapeutic interval were calculated as “conditional” R2, a pa-
rameter that includes random subject variability.19
Patients with suspected LOR
These patients were divided into 2 subgroups: those who 
experienced a decrease in FL after treatment and those who ex-
perienced an increase in FL after treatment (see Fig. 1). These 
2 subgroups were modeled separately. Patients with FL levels 
within normal limits before and after drug infusion/injection 
were not included in the analysis—because by definition they 
were not experiencing a true disease flare. This analysis was a 
descriptive analysis to summarize the changes in FL after drug 
administration relative to baseline. As in the first (therapeutic 
interval) group, FL values were log-transformed before anal-
ysis. Analysis of HBI and PMSI before and after treatment (at 
3-month follow-up) was performed by independent (2-sample) 
t tests. To uniformly analyze the data, these clinical indices 
were rescaled to be between 0 and 1 by dividing each score by 
the maximum value for each scale; for HBI, the value 16 was 
used as the maximum value because all the scores >16 are con-
sidered severe (and 16 was also the highest value of the HBI in 
the dataset).
TABLE 1. Therapeutic Interval Group Characteristics
Demographics n = 31
Age, y, median (IQR) 46 (24)
Sex (men/women) 14/17
Smoker (% current, former, never) 16, 45, 39
Disease characteristics  
Disease type  
 CD, n (%) 21 (68) 
 UC, n (%) 10 (32) 
Disease duration, y, median (IQR) 6 (9)
Biologic, n (%)  
 Infliximab 18 (58) 
 Vedolizumab 6 (19) 
 Adalimumab 7 (23) 
CD location, n (%)  
 L1: ileal 4 (20)
 L2: colonic 6 (26)
 L3: ileocolonic 11 (54)
CD behavior, n (%)  
 B1: nonstricturing, nonpenetrating 16 (74)
 B2: stricturing  3 (16) 
 B3: penetrating  2 (10)
UC location (%)  
 E1: Ulcerative proctitis  1 (10)
 E2: Left-sided (distal)  2 (20)
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RESULTS
Therapeutic Interval Group
Table 1 shows the clinical features of the 31 patients in 
clinical remission tested for FL at various timepoints during 
the therapeutic interval. Of these, 68% had CD and 32% 
had UC, 58% were on infliximab, and 19% and 23% were on 
vedolizumab and adalimumab, respectively. Most patients with 
CD had nonstricturing/nonpenetrating colonic or ileocolonic 
disease, and most patients with UC had pancolitis.
Table  2 shows the FL values at baseline (before starting 
therapy) and at an early and a late timepoint during the 8-week 
(infliximab/vedolizumab) or 14-day (adalimumab) therapeutic in-
terval. Baseline FL values varied among patients. However, in all 
patients FL values dropped significantly (up to 99.9%) after the 
start of therapy, consistently with observed clinical response. In 
TABLE 2. FL During Therapeutic Interval
Patients Treated With Infliximab—FL Values (μg/mL)
Patient number, disease type, location-extent Baseline Interval First Value (week number) Interval Last Value (week number) 
1 UC—E3 9888 6.25 (3) 622 (5)
2 UC—E3 1653 6.25 (5) 19 (6)
3 UC—E2 362 6.25 (4) 142 (6)
4 UC—E2 541 6.25 (1) 43 (6)
5 CD—L3 400 6.25 (5) 9 (6)
6 CD—L3 407 6.25 (1) 6.25 (8)
7 CD—L3 330 72 (3) 194 (8)
8 CD—L2 437 47 (1) 238 (8)
9 UC—E3 444 19 (3) 85 (4)
10 CD—L1 9 6.25 (1) 6.25 (6)
11 CD—L3 362 6.25 (2) 241 (8)
12 CD—L1 67 6.25 (1) 6.25 (7)
13 CD—L2 448 6.25 (3) 6.25 (8) 
14 CD—L2 7285 683 (1) 1007 (5) 
15 CD—L3 5923 6.25 (1) 18 (8) 
16 CD—L2 583 61 (3) 65 (7) 
17 CD—L3 218 36 (1) 152 (8)
18 UC—E3 4262 6.25 (1) 10 (8)
 Patients Treated With Vedolizumab— FL Values (μg/mL)
Patient number, disease type, location-extent Baseline Interval First Value (week number) Interval Last Value (week number) 
19 UC—E3 4097 10 (1) 40 (7)
20 UC—E3 4019 73 (1) 380 (6) 
21 UC—E1 46 6.25 (3) 6.25 (5)
22 UC—E3 3978 66 (1) 420 (6) 
23 CD—L2 1464 66 (4) 172 (8)
24 CD—L3 337 6.25 (3) 6.25 (6)
 Patients Treated With Adalimumab— FL Values (μg/mL)
Patient number, disease type, location-extent Baseline Interval First Value (day number) Interval Last Value (day number)
25 CD—L2 654 6.25 (3) 6.25 (12)
26 CD—L3 297 6.25 (5) 6.25 (10)
27 CD—L3 166 29 (2) 98 (13)
28 CD—L3 97 6.25 (7) 6.25 (10)
29 CD—L3 434 43 (4) 68 (13)
30 CD—L1 57 20 (3) 30 (12)
31 CD—L1 93 10 (4) 63 (13)
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22/31 patients (71%), FL levels increased moving toward the infu-
sion/injection day, with the highest values recorded immediately 
before drug administration and the lowest values immediately 
afterward. The results of the analysis of variance F test for the 
effect of therapeutic interval showed a significant (P < 0.001; con-
ditional R2 = 0.769) progressive increase of FL over time. In 9/31 
(29%) of patients, FL levels were below detectability throughout 
the interval and were excluded from the analysis. On average, pa-
tients with undetectable FL values during the therapeutic interval 
had baseline FL levels 9 times lower than patients with detectable 
levels. This finding suggests that standard medication dosage/in-
terval induced a deeper remission (with persistently undetectable 
FL) in patients with a lower disease burden.
Fig. 2 is a scatterplot with a Loess smoother that shows 
the pattern of percentage of baseline FL levels as a percentage 
of therapeutic interval. Supplementary Fig. 1 is a line graph 
that connects the individual patient values and shows the up-
ward trend for all patients. Hence, as the therapeutic interval 
progresses, FL levels increase—more so toward the end of the 
interval—thus reflecting the surge in inflammation as the drug 
concentration decreases over time.13
Patients With Suspected LOR
There were 30 consecutive patients on maintenance 
therapy experiencing a possible disease flare (newly reported 
pain and/or diarrhea and/or bleeding). Their features are shown 
in Table 3. Their mean age was 44 years, 57% were men, 63% 
had CD, 67% were on infliximab, 30% were on adalimumab, 
and 3% were on vedolizumab. The majority of patients with 
CD had colonic or ilecolonic nonstricturing/nonpenetrating di-
sease. The majority of patients with UC had pancolitis. 
The FL values before and after drug administration (see 
Fig. 1) separated 3 subgroups. In the first subgroup, FL was ele-
vated before infusion/injection and continued to increase there-
after ("nonresponders"). In the second subgroup, FL was also 
elevated before infusion/injection but decreased significantly 
without returning to normal after infusion/injection ("partial 
responders"). A  third subgroup displayed normal FL values 
after drug administration and in 9/10 patients even before drug 
administration ("responders"). 
Table 4 shows the clinical picture of these 3 subgroups of 
patients at the time of drug administration, the FL values be-
fore and after infusion/injection, the management strategy, and 
the 3-month outcomes—including the clinical indices before/
after the management decision and the follow-up FL meas-
ured before infusion/injection (also expressed as a percentage 
of premanagement values). The total follow-up time and addi-
tional changes in disease management are also shown in Table 4. 
In the first subgroup, the biologic was switched (in most pa-
tients to a different class). Two of these patients failed the new 
medication and required surgery. One of these patients had al-
ready failed other biologics and directly opted for surgery. One 
patient underwent urgent surgery because of severe colitis and 
FIGURE 2. Loess smoother of FL changes during the therapeutic 
interval in patients with IBD treated with biologics. Colored points de-
note patients’ first (yellow) and subsequent (purple) measurements.
TABLE 3. Characteristics of Patients With Suspected 
LOR
Demographics n = 30
Age, y, median (IQR) 44 (29)
Sex (men/women) 17/13
Smoker (% current, former, never) 14, 41, 45
Disease characteristics  
Disease type  
 CD, n (%) 19 (63)
 UC, n (%) 11 (37)
Disease duration, y, median (IQR) 9 (11)
Biologic, n (%)  
 Infliximab 20 (67)
 Vedolizumab 1 (3)
 Adalimumab 9 (30)
CD location, n (%)  
 L1: ileal 3 (16)
 L2: colonic 7 (37)
 L3: ileocolonic 9 (47)
CD behavior, n (%)  
 B1: nonstricturing, nonpenetrating 16 (84)
 B2: stricturing 2 (11)
 B3: penetrating 1 (5)
UC location (%)  
 E1: Ulcerative proctitis 2 (18)
 E2: Left-sided (distal) 3 (27)
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died of complications during surgery. Total follow-up time in 
this group averaged 18 months. In the second subgroup, FL de-
creased on average by approximately 70% after infusion/injec-
tion. In these patients, the therapeutic interval was decreased by 
2 to 4 weeks (infliximab/vedolizumab) or 1 week (adalimumab). 
In 1 patient, another medication (azathioprine 3 mg/Kg) was 
added because the patient was already on the shortest biologic 
therapeutic interval. Total follow-up time in this group aver-
aged 19 months. In the third subgroup of patients (responders), 
the therapy was left unchanged and other causes for the symp-
toms were sought and found for all. 
In most patients, hemorrhoids were found to be responsible for 
rectal bleeding while pain and diarrhea were attributed to a number 
of causes including nerve entrapment, hernia, short gut syndrome, 
and food poisoning, which mostly resolved after adequate manage-
ment. Total follow-up time in this group averaged 23 months. Fig. 3 
graphically illustrates the results for 3 different patients representing 
nonresponders, partial responders, and responders.
Disease severity was scored before and after (at 3 months) 
the management decision for all subgroups. Analysis of standard-
ized clinical scores showed that in nonresponders the initial scores 
(at time of drug administration) were higher than in partial re-
sponders (P = 0.002). However, the subgroup-tailored manage-
ment strategy led to a significant decrease in standardized clinical 
scores for both partial responders (0.58 ± 0.21 vs 0.13 ± 0.09; 
P < 0.001) and nonresponders (0.81 ± 0.17 vs 0.12 ± 0.08; 
P < 0.001). The FL level was measured (immediately before drug 
administration) at 3 months in all patients, except for those who 
had undergone surgery. It decreased on average by 88% and 97% 
compared to corresponding values at the time of index drug ad-
ministration in nonresponders and partial responders, respectively.
DISCUSSION
LOR and PNR to biologic agents occur frequently in 
IBD.20, 21 Traditionally, management has involved empirical 
drug dose escalation with subsequent medication switch in the 
absence of symptomatic improvement.20, 21 More recently, TDM 
has gained popularity over this approach. A number of studies 
have indeed shown that TDM may impact the management of 
LOR and PNR and has also helped clarify some of their mech-
anistic aspects.2, 3 However, several clinical issues (most notably 
the absence of universally applicable TL) limit the routine use 
of TDM strategies in daily practice.4-9, 11, 13, 22 a more practical 
approach would be to directly evaluate medication impact on 
disease activity and inflammatory burden—of which FL/FC 
are excellent indicators.23-29 However, their precise role in IBD 
management is still partly undefined,12 and in particular it is un-
clear whether fecal markers may reflect immediate drug efficacy 
in a timely way—a feature needed to manage LOR. 
In this retrospective study, we collected data generated in 
our clinical practice confirming initial FC data by our group13 
and providing evidence that FL levels bear a fine time-sensitivity 
to drug-generated changes in inflammation. In 71% of patients 
in clinical remission, FL levels increased during the therapeutic 
interval with the highest values recorded immediately before 
infusion/injection—mirroring increasing inflammatory ac-
tivity because of depletion of circulating drug levels in a timely 
way.13 Hence, the majority of patients with IBD successfully 
treated with biologics had FL levels above normal, especially 
approaching drug administration. This finding is significant be-
cause complete mucosal healing and normal fecal markers cor-
relate with better outcomes in the long term.30, 31 However, dose 
escalation in all such patients would increase costs and poten-
tially increase the risk of adverse effects.32 In patients with per-
sistently normal FL levels during the entire therapeutic interval, 
baseline FL values were almost an order of magnitude lower 
than in the other patients, suggesting that the standard biologic 
dose/interval was sufficient to afford a tight control of inflam-
mation and could in theory even be de-escalated.33, 34 Because 
fecal marker levels change during the therapeutic interval in 
FIGURE 3. FL levels in patients with IBD apparently losing response after a period of remission. A, Nonresponder (patient 3; see Table 4): FL levels 
before drug administration were elevated and increased further thereafter. The medication was switched and the patient regained response. B, 
Partial responder (patient 11; see Table 4): FL levels before drug administration were elevated and decreased afterward. The medication therapeutic 
interval was shortened and the patient regained response. C, Responder (patient 22; see Table 4): FL levels before drug administration were normal 
and did not change after drug administration. No changes were made in IBD medications and other causes of symptoms were sought (in this pa-
tient, bleeding resulted from hemorrhoids and ceased after surgery). Patient continued to respond to IBD medication. Day 0 arbitrarily indicates the 
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most patients, individual single-point values should be inter-
preted in the context of their timing of testing in relation to 
drug administration. For example, a normal value immediately 
before infusion/injection is more suggestive of deep remission 
than a normal value immediately after drug administration.
The fecal marker time sensitivity to drug-induced 
changes in inflammation was confirmed and leveraged in the 
group of patients with suspected LOR. In these patients, FL 
measured immediately before and immediately after infusion/
injection distinguished 3 groups of patients: one group had 
normal FL levels that remained normal after drug administra-
tion (responders), another group had elevated FL levels that 
partly decreased after infusion/injection but remained well 
above the normal threshold (partial responders), and a third 
group showed an increase in FL levels after drug administration 
(nonresponders). The increase in FL after infusion/injection in 
the latter group was expected because in the absence of thera-
peutic response, inflammation would continue to increase with 
time. The first group was managed conservatively, and a cause 
other than LOR for the apparent flare was actively sought (and 
found) in most of the patients (eg, hemorrhoids causing rectal 
bleeding). In nonresponders the medication was switched or 
surgery was performed for multiple biologic failures, with ex-
cellent clinical results at the 3-month follow-up time. In par-
tial responders the therapeutic interval was decreased, with 
reinduction of clinical remission in most patients at 3 months. 
Furthermore, in the latter 2 groups the 3-month FL (performed 
at the end of the new drug/new therapeutic interval) dropped 
on average by 88% and 97%, respectively. 
The average total follow-up time in the 3 groups of pa-
tients was 20 months (range, 4-48 months) during which most 
patients in each group continued to be successfully managed 
with the strategy adopted at the time of disease flare. However, 
1 patient among the nonresponders and 1 patient among the 
partial responders developed resistance to the new medica-
tion. More important, 4 patients among the nonresponders 
needed surgery, as opposed to none in the other groups. 
Multiple biologic failures over time were more common among 
nonresponders4 than among partial responders and responders 
(1 and 0, respectively). This result suggests that biologic failures 
identify a group of difficult-to-treat patients: those more likely 
to undergo surgery.
The main limitation of our study is its retrospective na-
ture, reflecting the clinical practice and strategies applied in our 
center. The patient population studied here was diverse in terms 
of disease type, location and extent, medications and routes 
used (intravenous vs subcutaneous), length of therapeutic in-
terval, and previous biologic use. However, such heterogeneity 
is actually one of the strengths of the study, confirming that 
this strategy is applicable across the entire spectrum of di-
sease expression and biologic therapies, a crucial feature for 
its practical routine use. However, adopting this strategy may 
be challenging if  the disease only involves a short small bowel 
segment, when fecal marker levels may not be always elevated.35 
Nevertheless, as shown herein, any baseline FL level signifi-
cantly above normal may be the only prerequisite to apply this 
strategy.
Notably, in patients experiencing a possible flare, ster-
oids or any other effective fast-acting medications given after 
symptom onset and before/during the double FL testing could 
affect the results. In our patients no concomitant medications 
were given in this period. If  clinically needed (ie, patients ex-
periencing symptoms several weeks before the next drug infu-
sion/injection), steroids could be initiated and kept on a stable 
dose well before and after the double FL testing—an approach 
that is classically used in clinical trials.
Finally, TL and ADA could have added insightful in-
formation to the study, but they were not determined. Future 
prospective studies should compare TDM to the strategy 
proposed here—in terms of  both accuracy and costs—and 
to endoscopy and symptom-based management. They should 
also clarify whether FL should be tested at different times 
according to the rate of  drug concentration decline during 
the therapeutic interval, identify potential FL cutoff  levels in 
different scenarios, and clarify whether FC could be used in 
place of FL.
CONCLUSIONS
The timely sensitivity of FL to drug-generated changes in 
inflammation provides the rationale for an accurate and inex-
pensive stool marker–based strategy to manage LOR. Larger, 
prospective studies may be needed to confirm our findings and 
evaluate any potential complementary role for TDM.36
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
Supplementary Figure 1. FL changes during the thera-
peutic interval in patients with IBD treated with biologics: line 
graph connecting individual patient values (represented by the 
same color).
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